Geneticure is a precision medicine company with operations in Arizona and Minnesota that develops genetic tests to personalize hypertension treatment. Its non-invasive cheek swab analyzes four physiologic pathways to predict whether a patient with resistant hypertension will respond to renal denervation and to guide daily medication selection. The company holds four U.S. patents, runs testing through a CAP-accredited, CLIA-certified genomics core, and reported 96% sensitivity for its renal denervation responder score in a blinded pilot study.
1
Round
1
Industry
5
Tags
Oct 21, 2026
Latest raise
Funding activity · 1 round
Oct 21, 2026
$1M
Seed
Led by Xcellerant Ventures
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
